4 completed. 2 Phase 2, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
| Phase 3 | 1 | Completed 1 |
| Phase 4 | 1 | Completed 1 |
Follow Pertussis Immunisation: new trials by email Literature Review of Pertussis Immunisation trials Research Report on Pertussis Immunisation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Immune Response After Booster Vaccination With Tdap-IPV Vaccine (Against Tetanus, Diphtheria, Pertussis and Poliomyelitis) in Children Who Received Different Pertussis Primary Vaccine Regimens in Republic of South Africa Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Combined with Inactivated Poliomyelitis Vaccine - Pertussis Immunisation, Diphtheria Immunisation | Phase 4 | Completed | Sanofi Pasteur, a Sanofi Company | 273 | 2021-01-27 | 2025-09-12 |
| Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand DTwP-HepB-Hib-IPV hexavalent vaccine (Diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b, inactivated poliovirus), DTwP-HepB-Hib pentavalent vaccine (Diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b), Inactivated Poliomyelitis Vaccine - Pertussis Immunisation, Diphtheria Immunisation | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 460 | 2020-06-28 | 2025-09-22 |
| Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants Pneumococcal Conjugate Vaccine formulation 1, Pneumococcal Conjugate Vaccine formulation 2, Pneumococcal Conjugate Vaccine formulation 3 - Pneumococcal Immunisation, Diphtheria Immunisation | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 852 | 2020-05-22 | 2025-09-08 |
| Safety and Immunogenicity of Intranasal BPZE1 Vaccination in Healthy Adults BPZE1, Placebo - Pertussis, Pertussis Immunisation | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 50 | 2018-10-23 | 2024-09-19 |
Whooping Cough (1)
Bacterial Infections (1) · Bacterial Infections and Mycoses (1) · Bordetella Infections (1) · Gram-Negative Bacterial Infections (1) · Infections (1) · Respiratory Tract Diseases (1) · Respiratory Tract Infections (1)
Tetanus Toxoid (3) · 13-valent pneumococcal vaccine (2) · Poliovirus Vaccine, Inactivated (2) · CRM197 (non-toxic variant of diphtheria toxin) (1) · Chickenpox Vaccine (1) · Diphtheria Toxoid (1) · Engerix-B (1) · Hepatitis B Surface Antigens (1) · Hepatitis B Vaccines (1) · Herpes Zoster Vaccine (1) · Measles-Mumps-Rubella Vaccine (1) · RIX4414 vaccine (1) · RotaTeq (1) · Rotavirus Vaccines (1) · pentacel (1)
Sanofi Pasteur, a Sanofi Company (3) · National Institute of Allergy and Infectious Diseases (NIAID) (1)
United States (2) · Canada (1) · Honduras (1) · Puerto Rico (1) · South Africa (1) · Thailand (1)